After Leerink Partners and Ladenburg gave Vericel Corp (NASDAQ: VCEL) a Buy rating last month, the company received another Buy, this time from BTIG. Analyst Ryan Zimmerman reiterated a Buy rating on Vericel Corp (NASDAQ: VCEL) yesterday and set a price target of $17. The company’s shares opened today at $9.15.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 23.5% and a 60.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and SeaSpine Holdings.
Currently, the analyst consensus on Vericel Corp is a Strong Buy with an average price target of $15, a 63.9% upside from current levels. In a report released yesterday, Ladenburg also upgraded the stock to Buy with a $13 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.75 and a one-year low of $3. Currently, Vericel Corp has an average volume of 1.16M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel.
